Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) was up 2.7% on Wednesday . The stock traded as high as $2.66 and last traded at $2.64, with a volume of 268,257 shares trading hands. The stock had previously closed at $2.57.

Separately, Maxim Group lowered their target price on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 21st.

The firm’s 50 day moving average is $2.89 and its 200 day moving average is $5.32. The stock’s market capitalization is $40.17 million.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.